
WilmerHale Reps Infinity Pharma in \$28M Licensing Agreement with Verastem

NOVEMBER 8, 2016

Verastem, Inc. and Infinity Pharmaceuticals, Inc. announced that the companies entered into a license agreement under which Verastem licensed exclusive worldwide rights to develop and commercialize Infinity's oncology product candidate duvelisib, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma being investigated for the treatment of hematologic cancers.

Verastem will pay Infinity up to \$28 million in milestones, with positive data from DUO®, a Phase 3, randomized monotherapy study of duvelisib in patients with relapsed/refractory CLL, triggering the first milestone payment, and royalties on net sales.

The WilmerHale deal team was led by Partners [Belinda Juran](#) and [Steven Singer](#) and included Associate [Alex Civetta](#).

Read [Infinity's press release](#) for more information.